These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 1787836

  • 1. Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells.
    Rodolfo M, Salvi C, Bassi C, Rovetta G, Melani C, Colombo MP, Parmiani G.
    Nat Immun Cell Growth Regul; 1991; 10(6):308-19. PubMed ID: 1787836
    [Abstract] [Full Text] [Related]

  • 2. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K, O'Donnell RW, Cockett AT.
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [Abstract] [Full Text] [Related]

  • 3. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.
    In Vivo; 1999 Feb; 13(3):199-204. PubMed ID: 10459491
    [Abstract] [Full Text] [Related]

  • 4. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS, Hargrove ME, Ting CC.
    Cancer Res; 1989 Sep 01; 49(17):4770-4. PubMed ID: 2527087
    [Abstract] [Full Text] [Related]

  • 5. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y.
    Hokkaido Igaku Zasshi; 1992 Jul 01; 67(4):475-87. PubMed ID: 1330859
    [Abstract] [Full Text] [Related]

  • 6. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines.
    Rodolfo M, Zilocchi C, Melani C, Cappetti B, Arioli I, Parmiani G, Colombo MP.
    J Immunol; 1996 Dec 15; 157(12):5536-42. PubMed ID: 8955204
    [Abstract] [Full Text] [Related]

  • 7. Production of interleukin 2 and interleukin 4 by immune CD4-CD8+ and their role in the generation of antigen-specific cytotoxic T cells.
    Horvat B, Loukides JA, Anandan L, Brewer E, Flood PM.
    Eur J Immunol; 1991 Aug 15; 21(8):1863-71. PubMed ID: 1907920
    [Abstract] [Full Text] [Related]

  • 8. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 9. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E, Eisenthal A, Sachs D, Rosenberg SA.
    J Immunol; 1987 Mar 15; 138(6):1992-8. PubMed ID: 3493293
    [Abstract] [Full Text] [Related]

  • 10. Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.
    Rodolfo M, Salvi C, Bassi C, Sensi M, Parmiani G.
    Ann Ist Super Sanita; 1990 Mar 15; 26(3-4):423-32. PubMed ID: 2091504
    [Abstract] [Full Text] [Related]

  • 11. IL-2 gene transfer in immunotherapy of cancer: local administration of IL-2-activated lymphocytes and X63-m-IL-2 cells constitutively producing IL-2 inhibits growth of plasmacytomas in syngeneic mice.
    Bubeník J, Lotzová E, Indrová M, Simová J, Jandlová T, Savary CA.
    Nat Immun Cell Growth Regul; 1991 Mar 15; 10(5):247-55. PubMed ID: 1758466
    [Abstract] [Full Text] [Related]

  • 12. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 13. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS, Miller CH, Graham L, Parviz M, Zacur S, Patel B, Duong A, Bear HD.
    Int Immunol; 2004 Sep 15; 16(9):1283-94. PubMed ID: 15262898
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G, Chiodoni C, Gallo E, Stoppacciaro A, Liew FY, Colombo MP.
    Cancer Res; 2002 Aug 01; 62(15):4390-7. PubMed ID: 12154045
    [Abstract] [Full Text] [Related]

  • 15. Differential in situ expansion and gene expression of CD4+ and CD8+ tumor-infiltrating lymphocytes following adoptive immunotherapy in a murine tumor model system.
    Evans R, Duffy TM, Kamdar SJ.
    Eur J Immunol; 1991 Aug 01; 21(8):1815-9. PubMed ID: 1907916
    [Abstract] [Full Text] [Related]

  • 16. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
    Basse PH.
    APMIS Suppl; 1995 Aug 01; 55():1-28. PubMed ID: 8534522
    [Abstract] [Full Text] [Related]

  • 17. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
    Chikkala NF, Lewis I, Ulchaker J, Stanley J, Tubbs R, Finke JH.
    Cancer Res; 1990 Feb 15; 50(4):1176-82. PubMed ID: 2297766
    [Abstract] [Full Text] [Related]

  • 18. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA, Custer MC, Rosenberg SA, Lotze MT.
    J Biol Response Mod; 1990 Apr 15; 9(2):113-26. PubMed ID: 2111373
    [Abstract] [Full Text] [Related]

  • 19. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M, Plautz GE, Shu S.
    Cancer Res; 1996 Oct 15; 56(20):4702-8. PubMed ID: 8840987
    [Abstract] [Full Text] [Related]

  • 20. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 15; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.